Wall Street analysts expect that Intersect ENT Inc (NASDAQ:XENT) will report ($0.40) earnings per share for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Intersect ENT’s earnings. The highest EPS estimate is ($0.34) and the lowest is ($0.46). Intersect ENT reported earnings per share of ($0.25) in the same quarter last year, which suggests a negative year-over-year growth rate of 60%. The company is scheduled to announce its next earnings results on Monday, November 4th.
On average, analysts expect that Intersect ENT will report full year earnings of ($1.44) per share for the current fiscal year, with EPS estimates ranging from ($1.50) to ($1.32). For the next year, analysts forecast that the firm will report earnings of ($1.31) per share, with EPS estimates ranging from ($1.43) to ($1.10). Zacks’ EPS calculations are an average based on a survey of research analysts that that provide coverage for Intersect ENT.
Intersect ENT (NASDAQ:XENT) last announced its quarterly earnings data on Thursday, August 1st. The medical equipment provider reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.02). Intersect ENT had a negative net margin of 31.43% and a negative return on equity of 29.16%. The firm had revenue of $26.66 million for the quarter, compared to analyst estimates of $27.13 million. During the same quarter in the previous year, the company earned ($0.14) EPS. The company’s quarterly revenue was up 1.4% compared to the same quarter last year.
Several large investors have recently bought and sold shares of XENT. Quantamental Technologies LLC grew its holdings in shares of Intersect ENT by 133.6% during the second quarter. Quantamental Technologies LLC now owns 4,555 shares of the medical equipment provider’s stock valued at $104,000 after purchasing an additional 2,605 shares during the last quarter. NumerixS Investment Technologies Inc increased its stake in shares of Intersect ENT by 190.9% in the first quarter. NumerixS Investment Technologies Inc now owns 6,400 shares of the medical equipment provider’s stock worth $200,000 after acquiring an additional 4,200 shares during the last quarter. Xact Kapitalforvaltning AB acquired a new position in shares of Intersect ENT in the first quarter worth $212,000. Cubist Systematic Strategies LLC increased its stake in shares of Intersect ENT by 106.1% in the second quarter. Cubist Systematic Strategies LLC now owns 18,013 shares of the medical equipment provider’s stock worth $410,000 after acquiring an additional 9,275 shares during the last quarter. Finally, A.R.T. Advisors LLC acquired a new position in shares of Intersect ENT in the second quarter worth $539,000. 96.22% of the stock is owned by institutional investors.
NASDAQ XENT traded down $0.33 on Tuesday, hitting $16.70. 1,350 shares of the stock traded hands, compared to its average volume of 359,601. The stock has a 50-day moving average of $16.86 and a 200 day moving average of $23.18. Intersect ENT has a twelve month low of $15.01 and a twelve month high of $35.87. The company has a market capitalization of $523.71 million, a P/E ratio of -21.95 and a beta of 0.72.
Intersect ENT Company Profile
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
Featured Story: Cost of Capital
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.